- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05432206
MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva (MedCanDem)
Randomized Double-blind Cross-over Placebo-controlled Trial to Study the Impact on Behavioral and Psychological Symptoms of Dementia of Medical Cannabinoids (CBD/THC) in Patients With Severe Dementia in Long-term Care Facilities in Geneva
The behavioral and psychological symptoms of dementia affect up to 80% of long-term facilities residents with severe dementia. They seriously alter the quality of life of patients, relatives, and health professionals. Management involves correcting somatic and psychiatric factors and implementing non-drug interventions. Nevertheless, often drug treatments must be introduced with the limitations related to their effectiveness and adverse effects.
The investigators hypothesize that medical cannabinoids will improve neuropsychiatric and behavioral symptoms of patients with severe dementia.
The investigators assessed the feasibility and safety of administering a cannabis oil that contains tetrahydrocannabinol (THC) and Cannabidiol (CBD) during an initial study of about two years, observing an overall improvement, excellent tolerance to the treatment, and the possibility of reducing or even stopping other drugs.
This research project aims to study the efficacy of medical cannabis oil in improving the quality of life of dementia patients experimenting with behavioral and psychological symptoms.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study design is a placebo-controlled cross-over trial. The patients, the relatives, the health care professionals, and the study staff will be blinded.
Medical cannabis treatment is a cannabis oil that contains THC and CBD in a 1:2 ratio. The initial dose of 7 drops (2.5 mg THC and 5 mg CBD) will be gradually augmented and adjusted individually to a maximum of 56 drops (20 mg THC and 40 mg CBD) per day, divided into two administrations. Placebo is an edible oil with the same color, smell, and flavor as medical cannabis oil given with the same dosage scheme.
Patients will take medical cannabis oil for 8 weeks, in addition to their usual treatments.
The study is divided into two 8-week periods. Participants will be randomized 1:1 between cannabinoids/placebo and placebo/ cannabinoids sequences and will receive the cannabis oil during one of these periods and the placebo during the other.
Participants will observe a wash-out week between the two study periods, and a final observation week without treatment intake is planned at the end of the second period.
Rating scales to evaluate the efficacy will be assessed before treatment, after 28 days, at the end of periods, and at the end of the study. Blood pressure will be evaluated daily. Vital signs, blood formula, and the reduction or discontinuation of other drugs will be recorded periodically. In addition, the health professionals' and relatives' appraisals will be recorded at five-time points.
A blood test at the beginning and the end of each period will allow the evaluation of the potential drug-drug interactions and the pharmacokinetics of cannabinoids. The cytochromes P450 (1A2, 2B6, 2C9, 2C19, 2D6, 3A4/5) enzymatic activity will be evaluated by phenotyping after Geneva micro-cocktail intake. The therapeutic drug monitoring will be measured at a steady-state characterizing the plasma through levels of THC, its two metabolites, 11-hydroxy-tetrahydrocannabinol and free carboxy-tetrahydrocannabinol, and CBD.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Federica Bianchi
- Phone Number: +41 76 4947150
- Email: f.crova-bianchi@fahpa.ch
Study Contact Backup
- Name: Fondation FAHPA
- Email: medcandem@fahpa.ch
Study Locations
-
-
-
Geneva, Switzerland, 1206
- Recruiting
- FAHPA
-
Contact:
- Federica Bianchi
- Email: f.crova-bianchi@fahpa.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with severe dementia from different origins (Alzheimer's disease, vascular, mixed)
- Clinical Dementia Rating ≥3
- Persisting behavior problems (Neuropsychiatric Inventory [NPI] score > 10) notwithstanding optimal conventional treatment
- SARS-CoV-2 recovered for two weeks, or SARS-CoV-2 fully vaccinated
- Consent obtained from the representative in the medical field according to art 378 Swiss Civil Code (SCC)
Exclusion Criteria:
- Severe organ deficiency such as cardiac, pulmonary, hepatic, renal insufficiency, or unstable heart rhythm
- Symptomatic orthostatic hypotension
- Major changes or instability of psychotropic medication in the week preceding the study enrolment
- Having taken THC and/or CBD in the 7 days before enrolment
- Hemoglobin < 10 g/dl
- Severe kidney failure defined by cockcroft calculation <30 ml/mn
- Alanine aminotransferase and aspartate aminotransferase > 3x upper limit of normal
- Any other medical conditions that would prevent participation in the whole study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cannabis Sativa Oil first, then Placebo
This arm will start with the active comparator for the first period and change to the placebo in the second period
|
Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
Hemp virgin seed oil
|
Experimental: Placebo first, then Cannabis Sativa Oil
This arm will start with the placebo for the first period and change to the active comparator in the second period
|
Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
Hemp virgin seed oil
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cohen-Mansfield Agitation Inventory Scale (CMAI)
Time Frame: 4 and 8 weeks - after 1 week washout
|
Change from baseline in the Cohen-Mansfield Agitation Inventory score.
Scores range from 29 to 203 - higher scores mean a worse outcome ( A total score >45 is usually regarded as clinically significant agitation).
|
4 and 8 weeks - after 1 week washout
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neuropsychiatric Inventory (NPI)
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Change from baseline in the Neuropsychiatric Inventory score.
Scores range from 0 to 144 - higher scores mean a worse outcome.
|
4 and 8 weeks - after 1 week wash-out
|
Unified Parkinson disease rigidity scale (UPDRS)
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Change from baseline in the Unified Parkinson disease rating scale (UPDRS - item 22) rigidity score.
Scores range from 0 to 4 - higher scores mean a worse outcome.
|
4 and 8 weeks - after 1 week wash-out
|
Pain (Doloplus)
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Change from baseline in the Doloplus score.
Scores range from 0 to 30 - higher scores mean a worse outcome.
|
4 and 8 weeks - after 1 week wash-out
|
Daily activity
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Change from baseline in the score evaluating the most incapacitating daily activity.
Scores range 0 to 10 - higher scores mean a greater difficulty for patients.
|
4 and 8 weeks - after 1 week wash-out
|
Behavioral Trouble
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Change from baseline in the score evaluating the most incapacitating behavioral trouble.
Scores range 0 to 10 - higher scores mean a greater trouble.
|
4 and 8 weeks - after 1 week wash-out
|
Evolution of dosages for each patient
Time Frame: 4 and 8 weeks
|
Dosage adjustments of medical cannabis and psychotropic drugs.
|
4 and 8 weeks
|
Change in enzymatic activity
Time Frame: 8 weeks
|
Change in cytochromes P450 (1A2, 2B6, 2C9, 2C19,2D6 and 3A4/5 ) enzymatic activities using Geneva cocktail approach.
|
8 weeks
|
Therapeutic Drug Monitoring
Time Frame: 8 weeks
|
Therapeutic drug monitoring of plasma concentrations of Tetrahydrocannabinol, 11-Hydroxy-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, Cannabidiol.
|
8 weeks
|
Endocannabinoids
Time Frame: 8 weeks
|
Evaluation of plasma levels of endocannabinoids - anandamide and 2-arachidonylglycerol.
|
8 weeks
|
Team
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Score evaluating the team's impression of change.
Scores range 1 to 7. Higher scores mean greater deterioration.
|
4 and 8 weeks - after 1 week wash-out
|
Family
Time Frame: 4 and 8 weeks - after 1 week wash-out
|
Score evaluating the family's impression of change.
Scores range 1 to 7. Higher scores mean greater deterioration.
|
4 and 8 weeks - after 1 week wash-out
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Count 1
Time Frame: 8 weeks
|
Red Blood Cells, White blood cells, Platelets x1000/mm3
|
8 weeks
|
Blood Count 2
Time Frame: 8 weeks
|
Haemoglobin g/dL
|
8 weeks
|
Blood Count 3
Time Frame: 8 weeks
|
Hematocrit %
|
8 weeks
|
Blood Count 4
Time Frame: 8 weeks
|
Neutrophiles,Lymphocytes, Monocytes, Eosinophils and Basophils %
|
8 weeks
|
Blood pressure
Time Frame: through study completion, an average of 5 months
|
Blood pressure measurements - systolic and diastolic mmHG.
|
through study completion, an average of 5 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sophie Pautex, Prof., HUG
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MedCanDem
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia With Behavioral Disturbance
-
Massachusetts General HospitalTerminatedAlzheimer's Dementia With Behavioral DisturbanceUnited States
-
Massachusetts General HospitalNot yet recruitingCognitive Impairment | Dementia | Alzheimer Disease | Dementia With Behavioral DisturbanceUnited States
-
University of PennsylvaniaNational Institute on Aging (NIA)RecruitingParkinson Disease | Lewy Body Dementia With Behavioral Disturbance | Lewy Body Parkinson Disease | Parkinson Disease DementiaUnited States
-
Rutgers UniversityUnknownAlzheimer Disease | Parkinson | Dementia, Alzheimer Type | Dementia With Lewy Bodies | Asperger Syndrome | Autistic Disorders Spectrum | Adhd | Lewy Body Dementia With Behavioral Disturbance (Disorder) | Dementia Frontal | Tremor EssentialUnited States
-
University of FloridaNational Institute on Aging (NIA)RecruitingLewy Body Dementia With Behavioral Disturbance | Lewy Body Parkinson Disease | Lewy Body DiseaseUnited States
-
University of FloridaNational Institute on Aging (NIA); Aster Labs, IncCompletedLewy Body Dementia With Behavioral Disturbance | Dementia, Vascular | Alzheimer DementiaUnited States
-
University of MichiganNational Institute on Aging (NIA)RecruitingLewy Body Dementia With Behavioral Disturbance | Lewy Body Disease | Lewy Body Variant of Alzheimer DiseaseUnited States
-
Solvay PharmaceuticalsTerminatedPsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeUnited States, Czech Republic, Estonia, Israel, Poland
-
University of RostockGerman Center for Neurodegenerative Diseases (DZNE)Completed
-
Icahn School of Medicine at Mount SinaiNational Institute on Aging (NIA)RecruitingDepression | Sleep DisturbancesUnited States
Clinical Trials on Cannabis Sativa Oil
-
Bayliss J. Camp, PhDRecruitingDriving Impaired | Cannabis SmokingUnited States
-
Centre for Addiction and Mental HealthCompleted
-
Roswell Park Cancer InstituteNational Institute on Drug Abuse (NIDA)Not yet recruitingCannabis DependenceUnited States
-
Wolfson Medical CenterUnknownDystonia | SpasticityIsrael
-
Parc de Salut MarTerminated
-
Bod AustraliaDrug Science, UKCompleted
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Rambam Health Care CampusCompleted1- Cancer Patients During Chemotherapy Treatment | 2- Use of Cannabis Comparing to Control Without Cannabis UseIsrael
-
Assaf-Harofeh Medical CenterTikun OlamWithdrawnHemodialysis | Protein-Energy Malnutrition | Appetite DisordersIsrael
-
TO PharmaceuticalsWithdrawn